San Carlos, CA, United States of America

Lisa M Schultze


Average Co-Inventor Count = 4.2

ph-index = 2

Forward Citations = 125(Granted Patents)


Company Filing History:


Years Active: 1999-2002

Loading Chart...
2 patents (USPTO):Explore Patents

Title: Innovator Profile: Lisa M. Schultze from San Carlos, CA

Introduction

Lisa M. Schultze, an accomplished inventor based in San Carlos, California, is recognized for her significant contributions to the field of pharmaceuticals through her innovative work related to nucleotide analog compositions. With two patents to her name, Lisa exemplifies the spirit of research and development in the biotechnology sector.

Latest Patents

One of Lisa's latest patents focuses on "Nucleotide Analog Compositions," which provides crystalline forms of adefovir dipivoxil alongside methods to prepare these crystals. This invention holds substantial potential for large-scale synthesis, ensuring that adefovir dipivoxil can be formulated into therapeutic dosages effectively. Notably, the invention includes an anhydrous crystal form of adefovir dipivoxil, demonstrating Lisa's commitment to advancing pharmaceutical science.

Her second patent, "Nucleotide Analog Composition and Synthesis Method," introduces a composition comprising bis(POC)PMPA and fumaric acid (in a 1:1 ratio). This innovative composition serves as an essential intermediate for preparing antiviral compounds and can be administered to patients for antiviral therapy or prophylaxis, especially through oral intake. Furthermore, the patent details methods for synthesizing PMPA and its intermediates, emphasizing a reaction that produces diethyl PMPA with an improved by-product profile compared to previous methods.

Career Highlights

Lisa has built her career at Gilead Sciences, Inc., a leading company in the biopharmaceutical industry, known for its focus on research and development of antiviral drugs. Her work at Gilead not only highlights her scientific expertise but also underlines her role in advancing significant medical therapies.

Collaborations

Working closely with talented colleagues like John D. Munger and John C. Rohloff, Lisa has participated in collaborative efforts that enhance her research and drive innovation. These partnerships reflect a culture of teamwork and shared goals within the scientific community, contributing to breakthroughs that have the potential to impact patient care positively.

Conclusion

Lisa M. Schultze represents a key figure in the realm of biotechnology, with her patents presenting novel solutions to the challenges in antiviral therapies. Her contributions at Gilead Sciences are indicative of her dedication to innovation and the betterment of healthcare through science. As an inventor, Lisa continues to inspire future generations in the field of pharmaceuticals.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…